Literature DB >> 9816059

Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells.

D Katayose1, J Gudas, H Nguyen, S Srivastava, K H Cowan, P Seth.   

Abstract

To evaluate the effects of the wild-type p53 expression in normal and tumor cells, we have constructed a recombinant adenovirus vector (E1 minus) expressing human wild-type p53 cDNA (AdWTp53). Infection of normal and tumor cells of lung and mammary epithelial origin with AdWTp53 resulted in high levels of wild-type p53 expression. Production of p53 protein following infection was dependent on the dose of AdWTp53 with maximum amounts of p53 produced following infection with 50 plaque-forming units/cell. AdWTp53 infection inhibited the growth of all human cell lines studied. However, tumor cells that were null for p53 prior to infection (H-358 and MDA-MB-157) and tumor cells that expressed mutant endogenous p53 protein (MDA-MB-231 and MDA-MB-453) were more sensitive to AdWTp53 cytotoxicity than cells that contained the wild-type p53 (MCF-7, MCF-10, 184B5, and normal mammary epithelial cells). All cells exhibited WAF1/Cip1 mRNA and protein induction following AdWTp53 infection. AdWTp53-induced cytotoxicity of human tumor cell lines expressing mutant p53 was mediated by apoptosis as revealed by nucleosomal DNA fragmentation analysis. No detectable nucleosomal DNA fragmentation was observed following AdWTp53 infection of human cells expressing wild-type p53. These data suggest that endogenous p53 status is a determinant of AdWTp53-mediated cell killing of human tumor cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9816059

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  20 in total

1.  XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A.

Authors:  Takahito Miyake; Sunila Pradeep; Sherry Y Wu; Rajesha Rupaimoole; Behrouz Zand; Yunfei Wen; Kshipra M Gharpure; Archana S Nagaraja; Wei Hu; Min Soon Cho; Heather J Dalton; Rebecca A Previs; Morgan L Taylor; Takeshi Hisamatsu; Yu Kang; Tao Liu; Sharon Shacham; Dilara McCauley; David H Hawke; John E Wiktorowicz; Robert L Coleman; Anil K Sood
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

2.  TGFβ-dependent induction of interleukin-11 and interleukin-8 involves SMAD and p38 MAPK pathways in breast tumor models with varied bone metastases potential.

Authors:  Janhavi Gupta; John Robbins; Tamas Jilling; Prem Seth
Journal:  Cancer Biol Ther       Date:  2011-02-01       Impact factor: 4.742

3.  Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice.

Authors:  A L Feldman; N P Restifo; H R Alexander; D L Bartlett; P Hwu; P Seth; S K Libutti
Journal:  Cancer Res       Date:  2000-03-15       Impact factor: 12.701

4.  Systemic delivery of a novel liver-detargeted oncolytic adenovirus causes reduced liver toxicity but maintains the antitumor response in a breast cancer bone metastasis model.

Authors:  Zhenwei Zhang; Jeffrey Krimmel; Zhiling Zhang; Zebin Hu; Prem Seth
Journal:  Hum Gene Ther       Date:  2011-06-08       Impact factor: 5.695

5.  Reactive oxygen species are downstream mediators of p53-dependent apoptosis.

Authors:  T M Johnson; Z X Yu; V J Ferrans; R A Lowenstein; T Finkel
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

6.  An Oncolytic Adenovirus Targeting Transforming Growth Factor β Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy.

Authors:  Yuefeng Yang; Weidong Xu; Di Peng; Hao Wang; Xiaoyan Zhang; Hua Wang; Fengjun Xiao; Yitan Zhu; Yuan Ji; Kamalakar Gulukota; Donald L Helseth; Kathy A Mangold; Megan Sullivan; Karen Kaul; Edward Wang; Bellur S Prabhakar; Jinnan Li; Xuejie Wu; Lisheng Wang; Prem Seth
Journal:  Hum Gene Ther       Date:  2019-07-01       Impact factor: 5.695

7.  Systemic Delivery of an Oncolytic Adenovirus Expressing Decorin for the Treatment of Breast Cancer Bone Metastases.

Authors:  Yuefeng Yang; Weidong Xu; Thomas Neill; Zebin Hu; Chi-Hsiung Wang; Xianghui Xiao; Stuart R Stock; Theresa Guise; Chae-Ok Yun; Charles B Brendler; Renato V Iozzo; Prem Seth
Journal:  Hum Gene Ther       Date:  2015-11-10       Impact factor: 5.695

8.  Mammary tumors initiated by constitutive Cdk2 activation contain an invasive basal-like component.

Authors:  Patrick E Corsino; Bradley J Davis; Peter H Nørgaard; Nicole N Teoh Parker; Mary Law; William Dunn; Brian K Law
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

9.  Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China.

Authors:  Guangyu Ma; Hideaki Shimada; Kenzo Hiroshima; Yuji Tada; Nobuo Suzuki; Masatoshi Tagawa
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

10.  A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFbeta signaling for breast cancer therapy.

Authors:  Z Hu; J S Robbins; A Pister; M B Zafar; Z-W Zhang; J Gupta; K J Lee; K Newman; K Neuman; C-O Yun; T Guise; P Seth
Journal:  Cancer Gene Ther       Date:  2009-10-02       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.